Corix Bioscience, Inc. (CXBS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Corix Bioscience, Inc. (CXBS) trades at $0.0001. Corix Bioscience, Inc. cultivates and extracts CBD oil from industrial hemp for medicinal applications. The company is headquartered in Phoenix, Arizona, and operates within the rapidly evolving cannabis industry. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CXBS: CXBS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CXBS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CXBS: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Corix Bioscience, Inc. (CXBS) Healthcare & Pipeline Overview
Corix Bioscience, Inc. focuses on the cultivation and extraction of CBD oil for medicinal purposes, operating in the competitive and evolving cannabis market. The company's position is influenced by regulatory changes, market demand for CBD products, and competition from both established pharmaceutical companies and other cannabis producers.
What Is the Investment Thesis for CXBS?
Corix Bioscience, Inc. presents a speculative investment opportunity within the high-growth CBD market. The company's focus on CBD oil extraction positions it to benefit from increasing consumer demand for alternative medicinal products. However, the company's small market capitalization ($0.00B) and high debt-to-equity ratio (1.41) indicate significant financial risk. Growth catalysts include potential expansion into new CBD product lines and favorable regulatory changes. Key risks include intense competition, fluctuating CBD prices, and the potential for stricter regulations. Investors should carefully consider the company's financial position and the volatile nature of the CBD market before investing.
Based on FMP financials and quantitative analysis
CXBS Key Highlights
The company's focus on planting, harvesting, and extraction provides vertical integration within the CBD supply chain.
- Corix Bioscience's headquarters are located in Phoenix, Arizona, a state with a developing cannabis industry.
- The company has a debt-to-equity ratio of 1.41, indicating a reliance on debt financing.
- Corix Bioscience does not currently offer a dividend, reflecting a focus on reinvesting earnings for growth.
Who Are CXBS's Competitors?
CXBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HEWA HealthWarehouse.com, Inc. | $0.11 | +0.00% | $6.29M | 55 |
| YI 111, Inc. | $3.44 | -1.99% | $30.1M | 44 |
| MYCOF Noveris Health Sciences Inc. | $0.73 | +0.00% | $42.7M | 48 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.42 | -1.42% | $213M | 47 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
| CGEM Cullinan Therapeutics, Inc. | $22.52 | +8.06% | $1.38B | 57 |
| DMRA Galecto, Inc. | $30.31 | -6.57% | $1.87B | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CXBS's Key Strengths?
Focus on the growing CBD market.
- Involvement in the entire CBD oil production process.
- Headquartered in a state with a developing cannabis industry.
- Potential for expansion into new product lines.
What Are CXBS's Weaknesses?
Small market capitalization.
- High debt-to-equity ratio.
- Limited brand recognition.
- Dependence on a single product (CBD oil).
What Could Drive CXBS Stock Higher?
CXBS catalyst: Potential changes in cannabis regulations at the state or federal level could create new market opportunities for Corix Bioscience.
- Increasing consumer awareness and acceptance of CBD products could drive demand for Corix Bioscience's CBD oil.
- Expansion into new product lines and geographic markets could accelerate revenue growth.
- Positive clinical trial results demonstrating the efficacy of CBD for specific medical conditions could boost investor confidence.
- Strategic partnerships and acquisitions could enhance Corix Bioscience's competitive position.
What Are the Key Risks for CXBS?
Intense competition from larger companies with greater resources.
- Fluctuating CBD prices could negatively impact profitability.
- Stricter regulations on CBD production and sales could limit market access.
- Negative publicity or health concerns related to CBD products could damage consumer demand.
- The company's high debt-to-equity ratio could constrain its ability to invest in growth initiatives.
What Are the Growth Opportunities for CXBS?
- Expansion into new CBD product lines: Corix Bioscience could diversify its product offerings beyond CBD oil to include edibles, topicals, and other CBD-infused products. The global CBD market is projected to reach $55.79 billion by 2028, offering significant opportunities for companies that can innovate and capture market share. This expansion would allow Corix to target a wider range of consumers and increase revenue streams. Timeline: 1-2 years.
- Strategic partnerships and acquisitions: Corix Bioscience could pursue strategic partnerships with established companies in the pharmaceutical, nutraceutical, or retail sectors to expand its distribution network and market reach. Acquisitions of smaller CBD companies could also provide access to new technologies, product lines, and customer bases. The timeline for such partnerships and acquisitions is dependent on market conditions and available capital, but could be pursued within the next 2-3 years.
- Geographic expansion: Corix Bioscience could expand its operations beyond Arizona to other states with favorable cannabis regulations. The U.S. cannabis market is projected to reach $47.6 billion in 2026, driven by increasing legalization and consumer demand. Expanding into new states would allow Corix to tap into new markets and increase its overall revenue potential. Timeline: 2-3 years.
- Development of proprietary CBD formulations: Corix Bioscience could invest in research and development to create proprietary CBD formulations with enhanced efficacy and bioavailability. This would differentiate the company from its competitors and create a competitive advantage in the market. The development of proprietary formulations could also lead to patent protection and increased pricing power. Timeline: 3-5 years.
- Focus on international markets: As cannabis regulations evolve globally, Corix Bioscience could explore opportunities to expand into international markets with high growth potential. Expanding into international markets would diversify the company's revenue streams and reduce its reliance on the U.S. market. Timeline: 3-5 years.
What Are CXBS's Competitive Advantages?
- First-mover advantage in specific regional markets.
- Proprietary extraction techniques for high-quality CBD oil.
- Established relationships with hemp farmers and suppliers.
- Brand recognition and customer loyalty in niche markets.
What Does CXBS Do?
Corix Bioscience, Inc., headquartered in Phoenix, Arizona, specializes in the production of cannabidiol (CBD) oil, catering to the medicinal market. The company engages in the entire process, from planting and harvesting industrial hemp to extracting CBD oil. Originally named American Housing Income Trust, Inc., the company transitioned its focus and rebranded as Corix Bioscience, Inc. in June 2017, signaling its entry into the burgeoning CBD industry. Corix Bioscience aims to capitalize on the growing demand for CBD-based products, which are marketed for various health and wellness applications. The company's operations are centered around cultivating high-quality hemp and employing efficient extraction methods to produce CBD oil. While the company's specific product lines and distribution channels are not detailed, it operates within a complex regulatory landscape that governs the production, sale, and marketing of CBD products. As a smaller player in the pharmaceutical sector, Corix Bioscience faces competition from larger, more established companies, as well as other CBD producers.
What Products and Services Does CXBS Offer?
- Cultivates industrial hemp plants.
- Extracts CBD oil from hemp.
- Provides CBD oil for medicinal purposes.
- Focuses on the production of cannabidiol (CBD) oil.
- Sells CBD oil to consumers and businesses.
- Operates primarily in the United States.
How Does CXBS Make Money?
- Cultivation and harvesting of industrial hemp.
- Extraction of CBD oil from hemp biomass.
- Sales of CBD oil to consumers and businesses.
- Potential for white-label manufacturing for other brands.
What Industry Does CXBS Operate In?
Corix Bioscience operates within the rapidly evolving cannabis industry, specifically focusing on the cannabidiol (CBD) market. This market has experienced significant growth due to increasing consumer interest in CBD's potential health benefits. However, the industry is characterized by intense competition, regulatory uncertainty, and fluctuating commodity prices. Companies like Corix Bioscience face competition from established pharmaceutical firms exploring CBD-based therapies, as well as numerous smaller CBD producers. The industry's future growth depends on factors such as regulatory changes, scientific validation of CBD's efficacy, and consumer acceptance.
Who Are CXBS's Key Customers?
- Individuals seeking CBD oil for medicinal purposes.
- Businesses that incorporate CBD oil into their products.
- Pharmacies and healthcare providers.
- Wellness and health stores.
Company Profile
Corix Bioscience, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Surprise, US. The company is led by CEO Christ Froese. CXBS has traded publicly since 2017.
Key Financial Metrics
Return on equity for Corix Bioscience, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CXBS trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
CXBS Financials
Bull Case vs Bear Case
Bull Case
- Focus on the growing CBD market.
- Involvement in the entire CBD oil production process.
- Headquartered in a state with a developing cannabis industry.
- Potential for expansion into new product lines.
Bear Case
- Small market capitalization.
- High debt-to-equity ratio.
- Limited brand recognition.
- Dependence on a single product (CBD oil).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CXBS Latest News
No recent news available for CXBS.
CXBS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CXBS.
Price Targets
Wall Street price target analysis for CXBS.
CXBS MoonshotScore
What does this score mean?
The MoonshotScore rates CXBS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christ Froese
CEO
Information on Christ Froese's background is limited. Publicly available sources do not provide detailed information about his career history, education, or previous roles before becoming CEO of Corix Bioscience, Inc. Further research into his professional background is needed to provide a comprehensive profile.
Track Record: Due to the limited information available on Christ Froese's background and tenure at Corix Bioscience, it is difficult to assess his track record. There is no readily available information on key achievements, strategic decisions, or company milestones under his leadership. Further research is needed to evaluate his performance as CEO.
CXBS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Corix Bioscience may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide audited financial statements. Investing in companies on the OTC Other tier carries a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud and scams.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements (if available).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has a functioning website with contact information.
- Company has been in operation for several years.
- Company is registered with the relevant regulatory authorities.
- Company has a physical address and contact information.
- Company's management team has relevant experience in the industry.
Common Questions About CXBS (Healthcare)
What does Corix Bioscience, Inc. do?
Corix Bioscience, Inc. is involved in the cultivation, harvesting, and extraction of cannabidiol (CBD) oil from industrial hemp plants. The company focuses on providing CBD oil for various medicinal applications, aiming to capitalize on the growing demand for CBD-based products in the health and wellness market.
What do analysts say about CXBS stock?
As of 2026-03-18, there is no readily available analyst coverage or consensus on CXBS stock. This may be due to the company's small market capitalization, OTC listing, and limited financial disclosure. Investors should conduct their own thorough research and due diligence before investing in CXBS, considering the company's financial position, growth prospects, and the risks associated with the CBD market and OTC trading.
What are the main risks for CXBS?
The main risks for Corix Bioscience, Inc. include intense competition in the rapidly growing CBD market, potential fluctuations in CBD prices impacting profitability, and the possibility of stricter regulations on CBD production and sales. The company's small market capitalization and high debt-to-equity ratio also pose financial risks. Additionally, negative publicity or health concerns related to CBD products could negatively impact consumer demand and the company's revenue.
What are the key factors to evaluate for CXBS?
Evaluate CXBS on fundamentals, analyst consensus, and risk factors. Corix Bioscience, Inc. presents a speculative investment opportunity within the high-growth CBD market. Not financial advice.
How frequently does CXBS data refresh on this page?
CXBS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CXBS's recent stock price performance?
Corix Bioscience, Inc. (CXBS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the growing CBD market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CXBS overvalued or undervalued right now?
Corix Bioscience, Inc. (CXBS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CXBS before investing?
Before investing in Corix Bioscience, Inc. (CXBS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on Corix Bioscience, Inc. is limited due to its OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be complete or up-to-date.
- The CBD market is subject to rapid changes in regulations and consumer preferences.